Loading stock data…
$0.83-0.43 (-33.81%)
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity.
Biomea Fusion, Inc. in the Healthcare sector is trading at $0.84 with a market capitalization of $129M. Wall Street consensus targets $7.00 (7 analysts), implying a +737.2% move over the next 12 months. The stock is currently near its 52-week low of $0.80, remaining 40.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.28M↓ | -$18.60M↓ | -$11.72M↑ | -$12.77M | -$12.77M |
| Net Income | -$20.74M↓ | -$16.41M↓ | $4.61M↑ | -$12.41M↓ | -$8.33M |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALE...